Medtech Innovation Event 2025

Adrian Hunn is the Director of Swiss Medtech, the national industry association representing Switzerland’s medical technology sector. With more than 20 years of experience in business and leadership, he brings a unique blend of strategic insight and operational expertise. Prior to joining Swiss Medtech, he served as CEO of a Swiss SME and held various leadership roles across the health and innovation landscape. Adrian holds an Executive MBA from IMD Lausanne and is actively engaged in shaping health policy and international collaboration.

Rodolphe Eurin is the former CEO of Hôpital de La Tour in Geneva, where he led a strategic and operational transformation from 2018 to 2024. Prior to that, he served as COO of a private hospital group. His career spans the pharmaceutical, Medtech, and healthcare sectors, with key roles at F. Hoffmann-La Roche and Medtronic’s EMEA Spine & Neurological division. Today, he advises healthcare leaders and organizations on strategy and the transformation of care delivery.

Marjan Kraak is the Managing Director of the Health Innovation Hub Aargau, a collaborative initiative in Health and Medtech built around the Baden Cantonal Hospital (KSB). With a strong track record in both industry and academia, she previously spent nine years fostering entrepreneurship at ETH Zurich, supporting founders in building teams, ventures, and market-ready solutions

Cyrill Gyger is CEO and Co-Founder of QUMEA, a company pioneering sensor-based mobility monitoring in institutional care. With a strong background in sensors, AI, and entrepreneurship, he has successfully scaled technology and HealthTech solutions internationally. At QUMEA, he bridges technological innovation with clinical realities, enabling early risk detection and practical support for care teams across Europe. Under his leadership, QUMEA received the Swiss Economic Award 2024 and the Swiss Medtech Award 2025.

Dominic Senn is the CEO & Co-founder of machineMD, a Swiss-American medical device company revolutionizing brain diagnostics using ocular biomarkers. He leads the development of neos™, a VR-based neurodiagnostic platform that enables fast, scalable, and non-invasive brain assessments. Under his guidance, machineMD has grown from inception to clinical use, backed by investors like Topcon Healthcare and partners such as Mass Eye and Ear and Mayo Clinic.

Andreas Hugi is Chief Technology Officer at AlveoliX, a Swiss biotech company pioneering organs-on-chip technology that mimics the human microenvironment for more predictive and ethical drug testing. With a background in Micro and Medical Technology and a Master’s in Biomedical Engineering, Andreas joined AlveoliX in 2018 and now leads the company’s technical development and production efforts.

Sasha Hugentobler is the Swiss National Contact Point (NCP) for Health at Euresearch, advising on EU Health research and innovation programmes across FP6, FP7, Horizon 2020, and Horizon Europe. She brings extensive experience from participating in multiple EU projects as a work package leader, task leader, and trainer. Sasha holds a PhD in biochemistry and reproductive physiology from the Universities of Galway and York.

Jimmy Bron is Deputy Head of the Swiss HealthTech Center (SHTC) at Switzerland Innovation Park Biel/Bienne, where he leads multidisciplinary R&D in MedTech and HealthTech. He oversees projects from digital health to smart diagnostics, supports early-stage start-ups, and connects key ecosystem players. As an Innovation Booster Silver Aging expert evaluator, he also helps shape strategic growth leveraging SHTC’s role as an Innosuisse-accredited research partner.

Matt Lapinski is the Co-Founder and CEO of Clee Medical, a Geneva-based neurotech start-up advancing the precision and scalability of minimally invasive neurosurgery. By combining real-time ultra-high-resolution imaging with AI-powered anatomical navigation, Clee Medical is redefining surgical accuracy and opening new possibilities for patient outcomes.

Alex Tanno is the CEO and Co-Founder of Hemetron, an ETH Zürich spin-off revolutionizing chronic care through at-home blood testing. With a background in blood diagnostics from ETHZ, Alex leads a team focused on improving treatment outcomes for patients with chronic inflammatory conditions, starting with rheumatology. Under his leadership, Hemetron has raised CHF 2.2 million and validated a working prototype for at-home inflammation testing.

Dr. Philip Zimmermann is the Co-Founder and CEO of Prevision Medicine AG, an ETH Zurich spin-off that provides a personalized drug test to guide oncologists in treatment decisions. He previously co-founded and led Nebion, a bioinformatics platform spin-off from ETH, which was acquired by Immunai in 2021. He then served as VP Business Development Europe at Immunai before launching Prevision Medicine in 2024.

Dr. med. Martin Hlavica is Co-Founder and CEO of Rhovica Neuroimaging AG. As a board-certified neurosurgeon, Martin leads the company’s mission to improve emergency care for patients at risk of elevated intracranial pressure, such as those suffering from severe head trauma or brain hemorrhage. Rhovica enables faster, safer bedside catheter placement and real-time brain pressure monitoring, helping save lives, improve neurological outcomes, and reduce hospital costs.

Clémence  Hermann is in charge of business development at Spirecut, a Swiss MedTech company founded in 2020 by Prof. Frédéric Schuind. Spirecut commercialises patented Sono‑Instruments® – ultrasound‑guided, minimally invasive surgical instruments that treat two of the most common hand‑surgery problems, trigger finger and carpal tunnel syndrome. Spirecut’s instruments let surgeons work with increased accuracy, helping patients heal faster, with less pain and no resulting scar.

Dr. Curzio Rüegg is CEO and CSO of XEMPERIA, a University of Fribourg spin-off dedicated to early breast cancer detection through a simple blood test. Trained in medicine, immunology, and molecular biology, Curzio brings over 30 years of expertise in cancer biology, biomarker discovery, and translational research. He previously served as Professor of Cancer Biology at the University of Lausanne and of Pathology at the University of Fribourg, and co-founded two other biotech startups, Diagnoplex and Novigenix.